TAM
ADMA icon

Tucker Asset Management’s ADMA Biologics ADMA Stock Holding History

Tucker Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,599
Closed -$42.8K – 1381
2023
Q2 		$42.8K Buy
11,599
+2,278
+24% +$8.44K 0.01% 285
2023
Q1 		$30.9K Buy
+9,321
New +$32.2K 0.01% 332

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Tucker Asset Management's ADMA Position: Q3 2023 in Review

Tucker Asset Management sold out of ADMA Biologics (ADMA) in Q3 2023, closing a stake of 11,599 shares — an estimated $42.8K sold.

Tucker Asset Management first reported a position in ADMA in Q1 2023 and held it in 2 quarters. The position peaked at $42.8K in Q2 2023. 188 funds tracked by Wall St. Rank hold ADMA as of Q3 2023.

  • Tucker Asset Management reported no remaining ADMA Biologics position as of Q3 2023 after selling out during the quarter.
  • Tucker Asset Management sold 11,599 ADMA Biologics shares in Q3 2023, an estimated $42.8K.
  • Tucker Asset Management first reported a position in ADMA Biologics in Q1 2023 and held it in 2 quarters.
  • Tucker Asset Management's ADMA Biologics position peaked at $42.8K in Q2 2023.
  • 188 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2023.

Based on Tucker Asset Management's 13F filing for Q3 2023, filed 4 Dec 2023.